Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new class of oral antidiabetic agents launched in 2012 to slow disease progression by lowering blood glucose levels via the urine16, have shown metabolic benefits and the ability to slow DKD progression in several clinical studies in recent years. Here, SLC5A2 is linked to diabetic kidney disease.